
Help, my dog needs a therapist
Lakshmi had left her with a friend with a dog when she moved abroad, which was causing the stress. Lakshmi later decided to take Ammu abroad with her. 'Most vets in India treat the physical symptoms. I have started consuming content by internationally known animal behaviourists now and understand the issues of my family dog better. Also, cats do get attached to humans, unlike the popular myth,' she says, adding that Ammu is the 'happiest girl now.'
You Can Also Check:
Chennai AQI
|
Weather in Chennai
|
Bank Holidays in Chennai
|
Public Holidays in Chennai
In the UK, when pets appear to suffer from a non-physical ailment, the veterinarian refers them to a qualified animal behaviourist. And if something happens to the animal at the hands of the behaviouralist, the licence is cancelled. But no such system exists in India.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Sudden Ringing in Your Ears? This Spray Might Help
Stop Tinnitus Now
Learn More
Undo
While mental health is a specialisation in human medicine, the govt veterinary science syllabus is mostly focused on livestock, and at most, there are a few sessions on how to handle animals ethically. Vets at Tamil Nadu Veterinary and Animal Sciences University (Tanuvas), Chennai, agree that there isn't much in the syllabus about
animal behaviour
but there is a ''lot of scope'' for it. 'Mostly, we get cases of dog-to-human or dog-to-dog aggression. If the aggression is directed against every stranger, it's difficult to treat. We try anti-anxiety drugs, tricyclic antidepressants and selective serotonin reuptake inhibitors which take eight weeks to start showing results, but more important is early socialisation,' says Dr K J.
'Whatever we learn on small animals such as dogs and cats and their behaviour, is from books and training programmes,' says Dr V Arun, a veterinarian from Chennai. It was during such a programme conducted by the veterinary association that vets like him learned to handle dogs and cats, he says.
The trainers in these programmes are invariably from the west, and their insights have been eye-opening, says Dr Arun.
'Cats, for example, get stressed in vet clinics by the presence of dogs. It was this learning that made me decide to open a facility exclusive for cats in Chennai.'
Psychological issues in pets are more pronounced now than a few decades ago as people are constantly moving cities, especially post-Covid, says Dr Yamini P Suresh, a Bengaluru-based vet. While animal psychology should ideally be a subject, 'animals can't communicate, and hence pet psychology isn't easy'. 'We do our best to learn their behaviour case by case once we start practising. Each animal is unique, and there is no one-size-fits-all treatment.'
What helps her detect signs of depression or anxiety in pets, she says, is that she had dogs and cats growing up. Yamini also refers her patients to qualified behaviourists when she senses there are no major medical issues. Ethology or the science of animal behaviour is still an emerging field in India, and while some vets such as Yamini are open to referring their clients to them, others aren't. 'I'm not against them, it's just that very few are qualified,' says Dr Arun.
'Vets are invariably pressed for time, dealing with 50-60 animals a day, and it is difficult for them to form a personal bond with each dog or cat, and remember their past behaviour, hence many refer them to me,' says Nivedita Prabhukumar, a Bengaluru-based canine behaviourist. But things have progressed a lot, she says. When she started out in 2013, 'animal training' was only about teaching dogs obedience, which often involved punishment, and the use of tools such as shock collars, she says.
'There are still trainers who still do that but in the past decade, the focus has started shifting to the animal's happiness.' For example, an extra five minutes at the vet clinic for the animals to settle down makes all the difference, as it's a highly stressful environment for them, she says. 'I also suggest wellness visits to the vet for puppies for no reason to reduce anxiety.'
Dr Sonika Sathish, a former govt vet from Kerala says, in India, 70% of pets need muzzling at vet clinics. When she moved to Canada recently, she found only 5% of the pets there wore muzzles. 'Even cats are calm in clinics here. The vets draw blood from the jugular vein, unthinkable in India because the animal will be thrashing around in fear,' she says.
'Pet parents in the west train the animals from birth or send them to puppy school. They walk them, socialise them and familiarise them with humans, all of which are crucial for their adult behaviour.'
In Nivedita's view, the information explosion has gone to the other extreme. 'Earlier I had to request people to take their pets with them outdoors, but now there are many who take them along on every weekend, for every trip. I have to beg them to give the animal some stability.'
Dogs and cats manage to survive in most circumstances, but for them to thrive, and live their best life, you need a combination of the pet parent, the doctor, the behaviouralist, even the groomer working together, says Dr Yamini.
'Like for a child, you need a village to raise a pet too. If one misses a sign, the other can spot it and address it.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Mint
26 minutes ago
- Mint
Inside Cipla's battle with ‘superbugs' as antibiotic resistance rises in India
Mumbai-headquartered drugmaker Cipla Ltd is bolstering its focus on a pipeline of drugs to fight infections caused by bacterial antimicrobial resistance in India, a growing health crisis. The company, a leader in the infectious diseases segment, has already launched two antibiotics targetting such superbugs, and sees the segment as a long-term focus area, a senior executive told Mint. 'Since we began our work on (antimicrobial drug resistance), our strategic plan has been to introduce three to four products in the AMR space over a 5-year horizon," Dr. Jaideep Gogtay, Cipla's global chief medical officer, said in an interview. 'I think it will be a long-term strategy. As a company which remains focused on India, there is no option for us to not be in the antibiotics segment," Gogtay added. Antimicrobial drug resistance occurs when microorganisms like bacteria or fungi evolve to resist the drugs designed to kill or inhibit them. These 'superbugs' render existing treatments ineffective and can lead to escalation of the infection, and cause death as well. Bacterial antimicrobial resistance was associated with 4.71 million global deaths in 2021, according to a Lancet study. This could increase to 39 million by 2050. India, which is one of the world's largest antibiotic markets, also has one of the highest burdens of drug resistance. Overuse of antibiotics is leading to increasing resistance in the community, while new drug development has not kept pace with the growing threat. 'Out of every 100 new drugs developed, only one or two are antibiotics. Although we know, in the future antibiotic-resistant infections are going to probably kill more people than cancer infections," Gogtay said. Globally, the development focus has shifted away from infectives and antibiotics to therapies like cancer and obesity, with most large pharma companies exiting antibiotic research. Cipla's pipeline Cipla has launched two drugs targeted at bacterial AMR in the past year. In May, it became the first company to launch plazomicin, marketed under brand name Zemdri, in India, a novel anti-microbial with demonstrated activity against multi-drug resistant bacteria and clinical efficacy in complicated urinary tract infections (cUTI). Clinical efficacy refers to how well a drug or treatment method achieves its intended effect under controlled clinical trials. Last year, Cipla partnered with Chennai-based Orchid Pharma Ltd to launch its novel antibiotic Cefepime-Enmetazobactam, which has been approved for the treatment of cUTIs, hospital-acquired pneumonia, and ventilator-associated pneumonia. The company plans to launch this year a non-antibiotic that can be used to prevent cUTIs without the risk of developing resistance. 'We are working with a partner, and the product has been approved in India. We will launch this product in India shortly," said Gogtay. For 2024-25, Cipla reported a revenue of ₹27,548 crore, up 8% year-on-year, while profit after tax surged 28% to ₹5,273 crore. How big is the market? The overall market for anti-infective drugs in India was ₹26,824 crore in May in terms of moving annual total (MAT) sales, according to pharma intelligence platform Pharmarack. Of this, antibiotics accounted for sales worth ₹23,127 crore. (MAT sales refers to total sales over the past 12 months, calculated on a rolling basis.) However, it is hard to zero in on the size of the market for drugs specifically targeted at drug-resistant bacteria, according to experts. Drugs that target antimicrobial drug resistance are given after the first or second line of antibiotics prove to be ineffective in treating a patient. However, as resistance increases, the market is growing. 'Here, what they (Cipla) seem to be trying to do is identify certain areas which may be meaningful over a period of time and try to get in early. They are trying to be early in an area that may become a lot more relevant in the future," said Prashant Nair, analyst for healthcare and pharma at Ambit Capital. Anti-infective medicines make for a key therapy segment for Cipla, after respiratory, cardiac and urology, said Nair. 'Most players who are strong in anti-infectives therapy may be looking at this space." Apart from Cipla, Wockhardt Ltd too has been sharpening its focus on antimicrobial drug resistance, with a pipeline of six novel antibiotics, of which two have been launched in India. As on 3 July, Cipla shares were down by about 1.4% each since the beginning of the year, while Wockhardt shares were up nearly 20% on NSE. The Nifty Pharma index was down more than 5% year-to-date.


Time of India
an hour ago
- Time of India
Biocon biologics receives European Commission approval for Vevzuo, Evfraxy Denosumab biosimilars for bone diseases
Biocon Ltd on Thursday said its arm Biocon Biologics Ltd has been granted marketing authorisation by the European Commission for Vevzuo and Evfraxy biosimilars of Denosumab used in the treatment of different bone diseases. The marketing authorisation for the European Union (EU) follows a positive opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on April 25, 2025, Biocon Ltd said in a regulatory filing. Vevzuo is authorised for the prevention of bone complications in adults with advanced cancer involving bone and the treatment of adults and skeletally mature adolescents with giant cell tumour (GCT) of bone. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Join new Free to Play WWII MMO War Thunder War Thunder Play Now Evfraxy is authorised for the treatment of osteoporosis in men and postmenopausal women, the treatment of bone loss linked to hormone ablation in men with prostate cancer at increased risk of fractures or the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adults, the company said. "The approval of Vevzuo and Evfraxy in Europe underscores our strong scientific expertise and commitment to expanding patient access to essential medicines, including to new therapeutic areas such as bone health," Biocon Biologics CEO & Managing Director Shreehas Tambe said. Live Events Further, Tambe said, "In the past 18 months, we have successfully secured regulatory approvals for three biosimilars in Europe and two in the UK. These Denosumab biosimilars mark another significant milestone in our rapid expansion and support for healthcare systems in the region."


Hans India
an hour ago
- Hans India
Karnataka: Kiran Mazumdar-Shaw Rejects CM Siddaramaiah's COVID-19 Vaccine Heart Attack Claims
Kiran Mazumdar-Shaw, who started Biocon, said it is not true that COVID-19 vaccines caused many heart attacks in Hassan. She said this idea can confuse people. The Chief Minister of Karnataka, Siddaramaiah, said more than 20 people had heart attacks in Hassan last month. He thought the vaccine might be the cause. He also said the vaccines were made too fast. Kiran Mazumdar-Shaw said the vaccines were tested carefully and made with strong safety rules. She said the vaccines saved many lives. Only a few people had side effects. She said people should trust science and facts, not blame the vaccine without proof. The government made a team to check the heart attack cases in Hassan. The team will report what they find in 10 days. The Health Ministry said studies show the vaccines are safe. There is no proof that vaccines cause sudden deaths. The Ministry said heart attacks can happen for many reasons like family history, health, lifestyle, or after having COVID-19.